L-Nutra’s second FMD™ is a 4-day meal program currently undergoing clinical testing at five different hospitals to evaluate whether it supports the body during chemotherapy and helps with decreasing side effects and recovery. Chemolieve® clinical trials are being conducted at the University of Southern California, Mayo Clinic, Leiden University, and the University of Genoa.
Chemolieve® is the first 4-day meal replacement based on proprietary dietary interventions to supply the body with important nutrients to reduce adverse side effects of chemotherapy and enhance death of cancer cells.
Patients undergoing prolonged periods of fasting prior to, during and after chemotherapy, have reported reduction in a wide range of side effects. Because cancer patients are generally unable or unwilling to fast for prolonged periods of time, and since one or more cycles of fasting and chemotherapy may lead to additional malnourishment and nutritional deficiencies, L-Nutra developed a proprietary food (Chemolieve®) designed to support chemotherapy treatment by selectively nourishing normal cells.
This product is based on discoveries made at leading US research universities including the finding that specific extreme diets can increase tumor cell death in breast, melanoma, glioma, neuroblastoma and a variety of other types of cancers.